SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class drugs based on advanced immune system modulation technologies, announced today it has received the formal Minutes from its December 1, 2006 milestone meeting with the Medicines and Healthcare Products Regulatory Agency UK (MHRA). The MHRA meeting cleared the way for MultiCell to prepare and submit the Clinical Trial Authorization (CTA) application, retain the MS centers where the clinical study will be conducted, and complete the manufacturing and formulation procedures for the Company’s lead therapeutics program, MCT-125.
